the jade acquisition also expands our development focus , and creates a diversified portfolio of ocular assets consisting of egp-437 and our iontophoretic delivery technology , complemented by a cmha-s-based product pipeline . our expanded product pipeline now includes both preclinical and clinical assets that collectively address large market opportunities affecting a wide range of patients suffering from eyesight-threatening diseases and disorders . 53 the cmha-s platform is based on hyaluronic acid ( ha ) , a naturally occurring polymer that is important in many physiological processes , including wound healing , tissue homeostasis , and joint lubrication . to create hydrogels , the ha is modified to create cmha-s that is then cross-linked together through the thiol groups . some products employ disulfide cross-linking while others utilize a polyethylene glycol diacrylate , or pegda , cross-linker . cross-linking slows degradation of the ha backbone and provides a matrix for incorporating therapeutic agents . variations in the number of thiols per molecule , the molecular weight of the polymer , the concentration of the polymer , the type of cross-linking , and incorporation of active ingredients , provides a highly versatile platform that can be tailored to a specific application . cmha-s can be formulated as gels or films . our first cmha-s-based product candidate , the eyegate ocular bandage gel ( obg ) , is a topically-applied eye drop formulation that has recently completed its first-in-man clinical trial . we have recently released positive top-line results in the first quarter of 2017 from this initial pilot trial evaluating the ability of eyegate obg to accelerate ocular surface re-epithelialization following photorefractive keratectomy ( prk ) . the eyegate obg eye drop creates a thin , durable and protective coating to the damaged surface of the eye , serving to facilitate and accelerate corneal re-epithelization . the eyegate obg is intended for the management of corneal epithelial defects , and to accelerate re-epithelization of the ocular surface following surgery , injection , and other traumatic and non-traumatic conditions . pilot preclinical studies suggest that the specific cmha-s chemical modification comprising the eyegate obg creates a favorable set of attributes , including prolonged retention time on the ocular surface , and a smooth continuous clear barrier without blur that can minimize mechanical lid friction , reduce repeat injury , and mechanically protect the ocular surface , allowing accelerated corneal re-epithelization . the gel is presently available commercially as a veterinary device indicated for use in the management of superficial corneal ulcers . manufactured by sentrx animal care and sold in the u.s. by bayer animal health as remend® corneal repair , the product has been used successfully for 5 years in dogs , cats and horses , without adverse effects . the composition of the veterinary product is identical to that of the eyegate obg . we do not have the rights to the cmha-s platform for animal health or veterinary medicine . in november 2016 , we had a formal meeting with the u.s. food and drug administration ( fda ) , which confirmed a 510 ( k ) de novo path for our device , the cmha-s product in an eye drop formulation ( 0.75 % concentration ) , which we refer to as the eyegate obg . on december 5 , 2016 , we announced data from the third stage or 30 subjects enrolled in the phase 1b/2a trial of our egp-437 product for the treatment of ocular inflammation and pain in post-cataract surgery . the dose ranging phase 1b/2a clinical trial was a multi-center , open-label trial enrolling up to 80 subjects who had undergone unilateral cataract extraction and implantation of a monofocal intra-ocular lens . the primary objective of the trial was to assess the safety and efficacy of iontophoretic egp-437 in these patients following surgery and determine the optimum dose and dosing regimen to design a prospective , double-masked , randomized , controlled trial . on july 9 , 2015 , we entered into an exclusive , worldwide licensing agreement with a subsidiary of valeant pharmaceuticals international , inc. ( valeant ) , through which we granted valeant exclusive , worldwide commercial and manufacturing rights to our egp-437 product in the field of anterior uveitis , as well as a right of last negotiation to license our egp-437 product for indications other than anterior uveitis ( the valeant agreement ) . there are four principal r & d milestones under the valeant agreement : ( i ) the phase 3 clinical trial , ( ii ) the endothelial cell count safety trial ( a screening tool used to verify that a patient 's cornea has an adequate endothelial cell density ) , ( iii ) the chemistry , manufacturing and controls , or cmc , validation , and ( iv ) the new drug application , or nda , filing with the fda ( collectively , the four milestones , and each individually , a milestone ) . under the valeant agreement , valeant paid to us an initial upfront payment of $ 1.0 million , and we are eligible to receive milestone payments totaling up to $ 32.5 million , upon and subject to the achievement of certain specified developmental and commercial progress of the egp-437 product for the treatment of anterior uveitis . as of december 31 , 2016 , we have received an aggregate of $ 4.225 million in upfront and milestone payments from valeant . in addition , we are eligible under the valeant agreement to receive royalties based on a specified percent of net sales of our egp-437 product for the treatment of anterior uveitis throughout the world , subject to adjustment in certain circumstances . story_separator_special_tag we will remain an emerging growth company until the earliest of ( a ) the last day of the fiscal year in which we have total annual gross revenues of $ 1 billion or more , ( b ) the last day of our fiscal year following the fifth anniversary of the date of the completion of our initial public offering , ( c ) the date on which we have issued more than $ 1 billion in nonconvertible debt during the previous three years or ( d ) the date on which we are deemed to be a large accelerated filer under the rules of the sec . results of operations comparison of years ended december 31 , 2016 and 2015 the following table summarizes the results of our operations for the years ended december 31 , 2016 and 2015 : replace_table_token_6_th collaboration revenue . collaboration revenue was $ 0.669 million for the year ended december 31 , 2016 , compared to $ 0 million for the year ended december 31 , 2015 , reflecting the jade acquisition and the accompanying collaboration revenue we now generate from the u.s. government grants . research and development expenses . research and development expenses were $ 8.423 million for the year ended december 31 , 2016 compared to $ 2.717 million for the year ended december 31 , 2015. the increase of $ 5.705 million in costs was primarily due to an increase in clinical and other activity , which we were able to undertake after our august 2015 follow-on offering and is also related to the initiation of our phase 3 clinical trial for the treatment of anterior uveitis , the phase 1b/2a trial for post-cataract surgery inflammation and pain , the development of and clinical trial for the eyegate obg , as well as research expenses attributable to the company 's egp-437-based and cmha-s-based product pipelines . general and administrative expenses . general and administrative expenses were $ 5.594 million for the year ended december 31 , 2016 , compared to $ 3.960 million for the year ended december 31 , 2015. the increase of $ 1.633 million was primarily due to increases in payroll , office and other expenses as company operations have expanded with the initiation in clinical activity related to the egp-437 phase 3 trials for the treatment of anterior uveitis , the phase 1b/2a trial for post-cataract surgery inflammation and pain , and the clinical trial for the eyegate obg , as well as the expansion of operations following the jade acquisition . other income ( expense ) , net . total other income ( expense ) , net was $ 0.003 million for the year ended december 31 , 2016 and $ ( 1.710 ) million for the year ended december 31 , 2015. the decrease of $ 1.714 million is due to a decrease in interest expense of $ 1.934 million , primarily related to the initial public offering , for the year ended december 31 , 2016 compared to the year ended december 31 , 2015 , partially offset by a change in the fair value of the warrant liability of $ 0.223 million recorded in the year ended december 31 , 2015. net loss attributable to common stockholders . net loss attributable to common stockholders was $ 13.343 million for the year ended december 31 , 2016 , compared to $ 16.615 million for the year ended 59 december 31 , 2015. the decrease of $ 3.272 million is primarily due to the deemed dividend on preferred stock of $ 8.222 million recorded in the year ended december 31 , 2015 , partially offset by the increase of expenses relating to the egp-437 phase 3 trials , the phase 1b/2a trial for post-cataract surgery inflammation and pain , and the clinical trial for the eyegate obg , and increased research and development expenses , general and administrative expenses , and other expenses to support these activities . story_separator_special_tag funding requirements and other liquidity matters our egp-437 combination product and our cmha-s-based product pipeline are still in various stages of clinical development . we expect to continue to incur significant expenses and increasing operating losses for the foreseeable future . we anticipate that our expenses will increase substantially if and as we : seek marketing approval for our egp-437 combination product and our cmha-s-based products ; establish a sales and marketing infrastructure to commercialize our cmha-s-based products in the united states , if approved ; add operational , financial and management information systems and personnel , including personnel to support our product development and future commercialization efforts . until such time , if ever , as we can generate substantial product revenue , we expect to finance our cash needs through a combination of equity offerings , debt financings , collaborations , strategic alliances and licensing arrangements . we do not have any committed external source of funds . to the extent that we raise additional capital through the sale of equity or convertible debt securities , the ownership interest of our stockholders will be diluted , and the terms of these securities may include liquidation or other preferences that adversely affect the rights of a common stockholder . debt financing , if available , may involve agreements that include covenants limiting or restricting our ability to take specific actions , such as incurring additional debt , making capital expenditures or declaring dividends . if we raise additional funds through collaborations , strategic alliances or licensing arrangements with pharmaceutical partners , we may have to relinquish valuable rights to our technologies , future revenue streams , research programs or product candidates , including our egp-437 product and our cmha-s-based products , or grant licenses on terms that may not be favorable to us . if we are unable to raise additional funds through equity or debt financings when needed , we may be required to delay , limit , reduce or terminate our

liquidity and capital resources since becoming a public company in 2015 , we have financed our operations from the three registered offerings of our common stock and convertible preferred stock , and milestone payments from our valeant license agreement and the u.s. government grants . from inception through december 31 , 2016 , the company raised a total of $ 73.845 million from such sales of our equity and debt securities , both as a public company and prior to our ipo , as well as approximately $ 4.9 million in payments received under our license agreements and u.s. government grants . in march 2016 , we issued approximately 690,000 shares of common stock , and paid approximately $ 0.300 million in cash , to fund the jade acquisition . on july 9 , 2015 , we received the initial $ 1.0 million upfront payment from valeant as provided under the valeant agreement . through december 31 , 2016 , we have received cash payments of $ 4.225 million under the valeant agreement , which are presented as cash and deferred revenue on our consolidated balance sheet . on may 24 , 2016 , we entered into an at the market offering agreement ( the atm agreement ) with h.c. wainwright & co. , llc ( the sales agent ) , to create an at the market equity program under which we can from time to time offer and sell up to 1,319,289 shares of its common stock through thesales agent .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```liquidity and capital resources since becoming a public company in 2015 , we have financed our operations from the three registered offerings of our common stock and convertible preferred stock , and milestone payments from our valeant license agreement and the u.s. government grants . from inception through december 31 , 2016 , the company raised a total of $ 73.845 million from such sales of our equity and debt securities , both as a public company and prior to our ipo , as well as approximately $ 4.9 million in payments received under our license agreements and u.s. government grants . in march 2016 , we issued approximately 690,000 shares of common stock , and paid approximately $ 0.300 million in cash , to fund the jade acquisition . on july 9 , 2015 , we received the initial $ 1.0 million upfront payment from valeant as provided under the valeant agreement . through december 31 , 2016 , we have received cash payments of $ 4.225 million under the valeant agreement , which are presented as cash and deferred revenue on our consolidated balance sheet . on may 24 , 2016 , we entered into an at the market offering agreement ( the atm agreement ) with h.c. wainwright & co. , llc ( the sales agent ) , to create an at the market equity program under which we can from time to time offer and sell up to 1,319,289 shares of its common stock through thesales agent .
```    
 Suspicious Activity Report : the jade acquisition also expands our development focus , and creates a diversified portfolio of ocular assets consisting of egp-437 and our iontophoretic delivery technology , complemented by a cmha-s-based product pipeline . our expanded product pipeline now includes both preclinical and clinical assets that collectively address large market opportunities affecting a wide range of patients suffering from eyesight-threatening diseases and disorders . 53 the cmha-s platform is based on hyaluronic acid ( ha ) , a naturally occurring polymer that is important in many physiological processes , including wound healing , tissue homeostasis , and joint lubrication . to create hydrogels , the ha is modified to create cmha-s that is then cross-linked together through the thiol groups . some products employ disulfide cross-linking while others utilize a polyethylene glycol diacrylate , or pegda , cross-linker . cross-linking slows degradation of the ha backbone and provides a matrix for incorporating therapeutic agents . variations in the number of thiols per molecule , the molecular weight of the polymer , the concentration of the polymer , the type of cross-linking , and incorporation of active ingredients , provides a highly versatile platform that can be tailored to a specific application . cmha-s can be formulated as gels or films . our first cmha-s-based product candidate , the eyegate ocular bandage gel ( obg ) , is a topically-applied eye drop formulation that has recently completed its first-in-man clinical trial . we have recently released positive top-line results in the first quarter of 2017 from this initial pilot trial evaluating the ability of eyegate obg to accelerate ocular surface re-epithelialization following photorefractive keratectomy ( prk ) . the eyegate obg eye drop creates a thin , durable and protective coating to the damaged surface of the eye , serving to facilitate and accelerate corneal re-epithelization . the eyegate obg is intended for the management of corneal epithelial defects , and to accelerate re-epithelization of the ocular surface following surgery , injection , and other traumatic and non-traumatic conditions . pilot preclinical studies suggest that the specific cmha-s chemical modification comprising the eyegate obg creates a favorable set of attributes , including prolonged retention time on the ocular surface , and a smooth continuous clear barrier without blur that can minimize mechanical lid friction , reduce repeat injury , and mechanically protect the ocular surface , allowing accelerated corneal re-epithelization . the gel is presently available commercially as a veterinary device indicated for use in the management of superficial corneal ulcers . manufactured by sentrx animal care and sold in the u.s. by bayer animal health as remend® corneal repair , the product has been used successfully for 5 years in dogs , cats and horses , without adverse effects . the composition of the veterinary product is identical to that of the eyegate obg . we do not have the rights to the cmha-s platform for animal health or veterinary medicine . in november 2016 , we had a formal meeting with the u.s. food and drug administration ( fda ) , which confirmed a 510 ( k ) de novo path for our device , the cmha-s product in an eye drop formulation ( 0.75 % concentration ) , which we refer to as the eyegate obg . on december 5 , 2016 , we announced data from the third stage or 30 subjects enrolled in the phase 1b/2a trial of our egp-437 product for the treatment of ocular inflammation and pain in post-cataract surgery . the dose ranging phase 1b/2a clinical trial was a multi-center , open-label trial enrolling up to 80 subjects who had undergone unilateral cataract extraction and implantation of a monofocal intra-ocular lens . the primary objective of the trial was to assess the safety and efficacy of iontophoretic egp-437 in these patients following surgery and determine the optimum dose and dosing regimen to design a prospective , double-masked , randomized , controlled trial . on july 9 , 2015 , we entered into an exclusive , worldwide licensing agreement with a subsidiary of valeant pharmaceuticals international , inc. ( valeant ) , through which we granted valeant exclusive , worldwide commercial and manufacturing rights to our egp-437 product in the field of anterior uveitis , as well as a right of last negotiation to license our egp-437 product for indications other than anterior uveitis ( the valeant agreement ) . there are four principal r & d milestones under the valeant agreement : ( i ) the phase 3 clinical trial , ( ii ) the endothelial cell count safety trial ( a screening tool used to verify that a patient 's cornea has an adequate endothelial cell density ) , ( iii ) the chemistry , manufacturing and controls , or cmc , validation , and ( iv ) the new drug application , or nda , filing with the fda ( collectively , the four milestones , and each individually , a milestone ) . under the valeant agreement , valeant paid to us an initial upfront payment of $ 1.0 million , and we are eligible to receive milestone payments totaling up to $ 32.5 million , upon and subject to the achievement of certain specified developmental and commercial progress of the egp-437 product for the treatment of anterior uveitis . as of december 31 , 2016 , we have received an aggregate of $ 4.225 million in upfront and milestone payments from valeant . in addition , we are eligible under the valeant agreement to receive royalties based on a specified percent of net sales of our egp-437 product for the treatment of anterior uveitis throughout the world , subject to adjustment in certain circumstances . story_separator_special_tag we will remain an emerging growth company until the earliest of ( a ) the last day of the fiscal year in which we have total annual gross revenues of $ 1 billion or more , ( b ) the last day of our fiscal year following the fifth anniversary of the date of the completion of our initial public offering , ( c ) the date on which we have issued more than $ 1 billion in nonconvertible debt during the previous three years or ( d ) the date on which we are deemed to be a large accelerated filer under the rules of the sec . results of operations comparison of years ended december 31 , 2016 and 2015 the following table summarizes the results of our operations for the years ended december 31 , 2016 and 2015 : replace_table_token_6_th collaboration revenue . collaboration revenue was $ 0.669 million for the year ended december 31 , 2016 , compared to $ 0 million for the year ended december 31 , 2015 , reflecting the jade acquisition and the accompanying collaboration revenue we now generate from the u.s. government grants . research and development expenses . research and development expenses were $ 8.423 million for the year ended december 31 , 2016 compared to $ 2.717 million for the year ended december 31 , 2015. the increase of $ 5.705 million in costs was primarily due to an increase in clinical and other activity , which we were able to undertake after our august 2015 follow-on offering and is also related to the initiation of our phase 3 clinical trial for the treatment of anterior uveitis , the phase 1b/2a trial for post-cataract surgery inflammation and pain , the development of and clinical trial for the eyegate obg , as well as research expenses attributable to the company 's egp-437-based and cmha-s-based product pipelines . general and administrative expenses . general and administrative expenses were $ 5.594 million for the year ended december 31 , 2016 , compared to $ 3.960 million for the year ended december 31 , 2015. the increase of $ 1.633 million was primarily due to increases in payroll , office and other expenses as company operations have expanded with the initiation in clinical activity related to the egp-437 phase 3 trials for the treatment of anterior uveitis , the phase 1b/2a trial for post-cataract surgery inflammation and pain , and the clinical trial for the eyegate obg , as well as the expansion of operations following the jade acquisition . other income ( expense ) , net . total other income ( expense ) , net was $ 0.003 million for the year ended december 31 , 2016 and $ ( 1.710 ) million for the year ended december 31 , 2015. the decrease of $ 1.714 million is due to a decrease in interest expense of $ 1.934 million , primarily related to the initial public offering , for the year ended december 31 , 2016 compared to the year ended december 31 , 2015 , partially offset by a change in the fair value of the warrant liability of $ 0.223 million recorded in the year ended december 31 , 2015. net loss attributable to common stockholders . net loss attributable to common stockholders was $ 13.343 million for the year ended december 31 , 2016 , compared to $ 16.615 million for the year ended 59 december 31 , 2015. the decrease of $ 3.272 million is primarily due to the deemed dividend on preferred stock of $ 8.222 million recorded in the year ended december 31 , 2015 , partially offset by the increase of expenses relating to the egp-437 phase 3 trials , the phase 1b/2a trial for post-cataract surgery inflammation and pain , and the clinical trial for the eyegate obg , and increased research and development expenses , general and administrative expenses , and other expenses to support these activities . story_separator_special_tag funding requirements and other liquidity matters our egp-437 combination product and our cmha-s-based product pipeline are still in various stages of clinical development . we expect to continue to incur significant expenses and increasing operating losses for the foreseeable future . we anticipate that our expenses will increase substantially if and as we : seek marketing approval for our egp-437 combination product and our cmha-s-based products ; establish a sales and marketing infrastructure to commercialize our cmha-s-based products in the united states , if approved ; add operational , financial and management information systems and personnel , including personnel to support our product development and future commercialization efforts . until such time , if ever , as we can generate substantial product revenue , we expect to finance our cash needs through a combination of equity offerings , debt financings , collaborations , strategic alliances and licensing arrangements . we do not have any committed external source of funds . to the extent that we raise additional capital through the sale of equity or convertible debt securities , the ownership interest of our stockholders will be diluted , and the terms of these securities may include liquidation or other preferences that adversely affect the rights of a common stockholder . debt financing , if available , may involve agreements that include covenants limiting or restricting our ability to take specific actions , such as incurring additional debt , making capital expenditures or declaring dividends . if we raise additional funds through collaborations , strategic alliances or licensing arrangements with pharmaceutical partners , we may have to relinquish valuable rights to our technologies , future revenue streams , research programs or product candidates , including our egp-437 product and our cmha-s-based products , or grant licenses on terms that may not be favorable to us . if we are unable to raise additional funds through equity or debt financings when needed , we may be required to delay , limit , reduce or terminate our

